Results 221 to 230 of about 536,196 (264)
Some of the next articles are maybe not open access.

Vaccine Adjuvants

Clinical Infectious Diseases, 1980
Nonreplicating, purified subunit or synthetic viral vaccines of the future are likely to be weak immunogens that will require immunopotentiation if they are to be effective. These marginal vaccines could be improved by combination with potent and safe immunologic adjuvants. The use of adjuvants should also reduce the amount of purified antigen required
openaire   +2 more sources

Adjuvant activity of incomplete Freund's adjuvant

Advanced Drug Delivery Reviews, 1998
The water-in-oil emulsion adjuvants developed by Jules Freund and coworkers have been, and continue to be, used in research and veterinary vaccines. Incomplete Freund's Adjuvant (IFA) has also been widely tested in humans where it was shown to augment antibody responses greater than other adjuvants, such as alum, and to be well tolerated.
, Jensen, , Savary, , Diveley, , Chang
openaire   +2 more sources

Vaccine adjuvants

Seminars in Veterinary Medicine and Surgery: Small Animal, 1997
Vaccine adjuvants provide enhanced immune responses to a variety of antigens. Unlike human vaccines that are limited to aluminum-based adjuvants, veterinary vaccines may contain a large number of substances either alone or in combination that act as vaccine adjuvants.
openaire   +2 more sources

Immunological adjuvants IV. Relationship between adjuvant activity and antigenicity in mycobacterial adjuvant

Experientia, 1971
Wahrend sich bei Endotoxinen der Adjuvanseffekt proportional zur Antigenitat verhalt, ist diese Beziehung bei dem aus Tuberkelbazillen isolierten Wachs D nicht der Fall.
T, Ishibashi   +3 more
openaire   +2 more sources

Genetic Adjuvants

2003
In 1992, the era of DNA vaccines began with the report of antibody production upon intradermal injection of mice with a plasmid vector expressing a foreign antigen (1). A rapid succession of subsequent manuscripts showed stimulation of immune responses, including cytolytic T cells, upon inoculation of expression-vectors specific for antigens derived ...
H C, Ertl   +10 more
openaire   +2 more sources

[Adjuvants].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017
It is estimated that only 5% of all patients who can principally benefit from specific immunotherapy (SIT) undergo this treatment. SIT represents the only curative treatment for allergic disorders and efficacy has been demonstrated with various allergens.
openaire   +3 more sources

ADJUVANTS

Annals of the New York Academy of Sciences, 1974
openaire   +2 more sources

Management of glioblastoma: State of the art and future directions

Ca-A Cancer Journal for Clinicians, 2020
Aaron Tan, David M Ashley, Giselle Lopez
exaly  

Home - About - Disclaimer - Privacy